Addition Therapeutics
The role involves leading the design and hands‑on execution of in vivo CAR‑T studies, including animal handling, model development, and data interpretation, while collaborating with cross‑functional teams to generate and integrate efficacy and cellular/molecular readouts. The scientist will also manage external CRO studies, ensure compliance, and contribute to study documentation and presentations.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Addition Therapeutics.
Right around the average for this role